Investigation of the Use of a Probiotic Supplement in People With Long COVID
Study Details
Study Description
Brief Summary
This study is a double-blinded randomised trial to assess the efficacy of a probiotic supplement in alleviating symptoms in people with Long COVID.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
240 participants with Long COVID will be randomly assigned to either a probiotic or placebo group in a 1:1 ratio for twelve weeks. Participants will track symptoms using an app for three weeks before the study, and for the last three weeks of the treatment. Participants will answer online questionnaires about their symptoms at 0, 4, 8, and 12 weeks. A subgroup of 60 participants will attend the laboratory for blood tests, cognitive function tests and gut microbiome analysis at 0 and 12 weeks. This group will also wear activity trackers for two weeks before the study, and for the final two weeks of the study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Probiotic Participants assigned to the probiotic group. |
Dietary Supplement: Probiotic
Probiotic taken daily for 12 weeks.
|
| Placebo Comparator: Placebo Participants assigned to the placebo group. |
Dietary Supplement: Placebo
Placebo taken daily for 12 weeks.
|
Outcome Measures
Primary Outcome Measures
- Fatigue severity scale (FSS) [12 weeks]
9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle
- FACIT fatigue scale [12 weeks]
Measure that assesses self-reported fatigue and its impact upon daily activities and function
- EQ-5D-5L [12 weeks]
Multi-attribute generic health status measure
- Ability to Participate in Social Roles and Activities - PROMIS Short Form 8a [12 weeks]
Evaluation of ability to participate in social roles and activities
- Ecological Momentary Assessment (EMA) app [12 weeks]
Symptom data collected using an app (sleep, fatigue, pain, breathlessness, light-headedness, cognitive difficulties)
Secondary Outcome Measures
- IBS-SSS [12 weeks]
Composite score of abdominal pain, number of days with abdominal pain, bloating/distension, satisfaction with bowel habits, and IBS-related quality of life
- Gastrointestinal Symptom Rating Scale [12 weeks]
15 items in five symptom clusters: Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation
- MRC Dyspnoea scale [12 weeks]
Assesses the degree of functional disability due to dyspnoea
- International. Physical Activity Questionnaire (short form) [12 weeks]
Assesses moderate-to-vigorous physical activity and sedentary behaviour
- Accelerometery data [12 weeks]
Longitudinal measurement of movement
- Cambridge Neuropsychological Test Automated Battery (CANTAB) [12 weeks]
Computer-based cognitive assessment system
- 16S rRNA sequencing [12 weeks]
Analysis of the composition and diversity of the gut microbiome
- Analysis of inflammatory markers [12 weeks]
Measurement of cytokines (including IL-8, IL-6) by ELISA
Eligibility Criteria
Criteria
Inclusion Criteria: Long COVID defined as National Institute for Health and Care Excellence (NICE) criteria for Long COVID (Persistent symptoms at least 12 weeks after a confirmed or suspected Covid-19 infection).
-
Exclusion Criteria: Significant co-morbidities - no pre-existing diagnosis of hypertension, diabetes, cerebrovascular, cardiovascular or peripheral vascular disease, coagulopathy or haematological disorder or current or recent cancer.
-
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sheffield Hallam University | Sheffield | United Kingdom | S1 1WB |
Sponsors and Collaborators
- Sheffield Hallam University
- Symprove UK
- Biomesight
Investigators
- Principal Investigator: Caroline Dalton, PhD, Sheffield Hallam University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ER45883322